Table 5.
Biological activities of new steroids from genus Sinularia.
| Drug Class | Compounds | Pharmacology | Activities | Ref |
|---|---|---|---|---|
| Cytotoxicity | sinubrasolide B (167) | against P388, MOLT 4 and HT-29 | ED50: 9.1, 4.8, 4.8 μM | [84] |
| sinubrasolide E (171) | against K562 | ED50: 9.9, 7.5 μM | [84] | |
| sinubrasolide A (166) | against MOLT 4 and HT-30 | ED50: 8.7, 7.6 μM | [84] | |
| 177–179 | against K562 and HL-60 | IC50: 36.28–93.43 μM | [74] | |
| 183 | against HeLa | IC50: 44.8 μM | [60] | |
| 184 | against HL-60 and HeLa | IC50: 7.3, 27.1 μM | [60] | |
| 188 | against HL-60, HepG2, SW480 | IC50: 33.53, 64.35, 71.02 μM | [55] | |
| 191 | against HepG2 and HeLa | IC50: 37.30, 19.32 μM | [50] | |
| sinubrasolide H (192) | against P388, MOLT-4, K-562 and HT-29 | IC50: 39.8, 28.6, 29.7, 24.4 μM | [48] | |
| sinubrasolide J (194) | against P388, MOLT-4, K-562 and HT-30 | IC50: 18.7, 17.2, 12.6, 11.2 μM | [48] | |
| sinubrasolide K (195) | against P388, MOLT-4, K-562 and HT-31 | IC50: 18.3, 13.7, 17.4, 20.5 μM | [48] | |
| sinubrasone A (197) | against P388D1, MOLT-4 | IC50: 37.2, 37.8 μM | [48] | |
| sinubrasone B (198) | against P388D1, MOLT-4, K-562, and HT-29 | IC50: 9.7, 6.0, 5.2, 7.6 μM | [12] | |
| sinubrasone C (199) | against P388D1, MOLT-4, K-562, and HT-29 | IC50: 5.7, 5.3, 12.1, 10.4 μM | [12] | |
| sinubrasone D (200) | against P388D1, MOLT-4, K-562, and HT-29 | IC50: 24.4, 31.2, 21.3, 36.5 μM | [12] | |
| leptosteroid (201) | against HepG2 and SW480 | IC50: 21.13, 28.65 μM | [46] | |
| sinubrassione (208) | against PANC-1 | IC50: 15.24 μM | [43] | |
| ximaosteroid E (210) | against HL-60 | IC50: 1.79 μM | [11] | |
| ximaosteroid F (211) | against HL-60 | IC50: 4.03 μM | [11] | |
| 212 | against MDA-MB-436, Hep3B, HT-29, and H157 | IC50: 17.15, 29.28, 30.06, 10.14 μM | [9] | |
| 213 | against MDA-MB-436, A549, Hep3B, HT-29 | IC50: 18.21, 41.71, 19.03, 10.38 μM | [9] | |
| erectsterate (217) | against A549, HT29, SNU-398 and Capan-1 | IC50: 40.55, 32.83, 15.57, 23.51 μM | [2] | |
| 16,17-epoxy-23-methylergostane (225) | against MCF-7 and MDA-MB-231 | IC50: 31.44, 25.67 μM | [19] | |
| 223 | inhibit androgen receptors | inhibition rate: >100%, 10 μM | [6] | |
| Anti-inflammatory | dissesterol (175) | IL-12 p40 inhibition | IC50: 4.0 μM | [82] |
| sinubrasolide H (192) | inhibit release of elastase | inhibition rate: 32.4%, 10 μM | [48] | |
| sinubrasolide J (194) | inhibit superoxide anion generation | inhibition rate: 32.1%, 10 μM | [48] | |
| sinubrasolide K (195) | inhibit superoxide anion generation | inhibition rate: 34.3%, 10 μM | [48] | |
| sinubrasolide L (196) | inhibit superoxide anion generation and release of elastase | inhibition rate: 26.3%, 25.0%, 10 μM | [48] | |
| sinubrasone C (199) | inhibit the release of elastase | inhibition rate: 58.8%, 10 μM | [12] | |
| sinubrasone D (200) | inhibit the release of elastase | inhibition rate: 66.3%, 10 μM | [12] | |
| sinleptosterol A (214) | inhibit superoxide anion generation and release of elastase | IC50: 7.07, 7.57 μM | [25] | |
| sinleptosterol B (215) | inhibit superoxide anion generation and release of elastase | IC50: 4.68, 4.29 μM | [25] | |
| sinulasterol A (226) | TNF-α inhibition | IC50: 51.1 μM | [5] | |
| sinulasterol B (227) | TNF-α inhibition | IC50: 22.7 μM | [5] | |
| Antidiabetic | 7α-hydroxy-crassarosterol A (178) | PTP1B inhibition | IC50: 33.05 μM | [74] |
| Immunosuppression | yalongsterol A (224) | inhibit T and B lymphocyte cells proliferation | IC50: 46.0, 56.5 μM | [22] |
| Antiviral | 165 | against H5N1 | inhibition rate: 55.16%, 1 ng/mL | [84] |